 | |
- close
- close
|
Marketwire
Nov 24
Comment
CAMBRIDGE, MA -- (Marketwire) -- 11/24/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals primarily for use in oncology, today
Marketwire
Nov 11
Comment
CAMBRIDGE, MA -- (Marketwire) -- 11/11/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), announced that John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development, will present an
Marketwire
Nov 9
Comment
CAMBRIDGE, MA -- (Marketwire) -- 11/09/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals primarily for use in oncology, today
Marketwire
Oct 26
Comment
CAMBRIDGE, MA -- (Marketwire) -- 10/26/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced it will report third quarter 2009 financial results on November 9, 2009. Following the release of the financial results, the Company
Marketwire
Oct 21
Comment
CAMBRIDGE, MA -- (Marketwire) -- 10/21/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced that it has executed an exclusive 10-year agreement to supply the Onalta(TM) 90-Y edotreotide radiotherapeutic to BioMedica Life
newratings.com
Oct 16
Comment
NEW YORK, October 15 (newratings.com) - Analysts at Brean Murray initiate coverage of Molecular Insight Pharma (ticker: MIPI) with a "buy" rating. The target price is set to $11. [more]
StreetInsider.com
Oct 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Molecular+Insight+%28MIPI%29+Said+Azedra+Study+Demonstrates+Positive+Safety+Profile+and+Durable+Objective+Tumor+Responses/4992748.html for the full story.
Marketwire
Oct 5
Comment
CAMBRIDGE, MA -- (Marketwire) -- 10/05/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today reported one-year follow-up data from a Phase I dose-escalation clinical study of Azedra(TM) demonstrating a positive safety profile and durable
Marketwire
Sep 4
Comment
CAMBRIDGE, MA -- (Marketwire) -- 09/04/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) will make a presentation at the Rodman and Renshaw 11th Annual Healthcare Conference on September 10, 2009 at 2 PM, Eastern Daylight Time. Daniel L.
Marketwire
Sep 2
Comment
CAMBRIDGE, MA -- (Marketwire) -- 09/02/09 -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced that it has completed an agreement to sub-license its Onalta(TM) brand 90-Y edotreotide radiotherapeutic in certain countries in
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
MIPI AT A GLANCE
References
| ||||||
|
|
